Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study.
Luiza Raquel GrazziotinGillian CurrieMarinka TwiltMaarten J IjzermanMichelle M A KipHendrik KoffijbergSusanne M BenselerJoost F SwartSebastiaan J VastertNico M WulffraatRae S M YeungNicole JohnsonNadia J LucaPaivi M MiettunenHeinrike SchmelingDeborah A Marshallnull nullPublished in: Rheumatology and therapy (2021)
The care pathway for children with JIA can be expensive, and complex-and varies by JIA subtype. Although the yearly total mean cost per patient was constant, the distribution of costs changes over time with the introduction of biologic therapies later in the care pathway. This study provides a better understanding of the JIA costs profile and can help inform future economic studies.